Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01020305
Other study ID # IRB-17242
Secondary ID SU-09292009-4080
Status Terminated
Phase Phase 1/Phase 2
First received October 30, 2009
Last updated October 3, 2014
Start date October 2009
Est. completion date April 2012

Study information

Verified date October 2014
Source Stanford University
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationUnited States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This study evaluates if temsirolimus causes a reduction in the serum levels of prostate-specific antigen (PSA) in male subjects with castration-resistant prostate cancer (CRPC).


Description:

Castration-resistant prostate cancer (CRPC) is also known as "androgen-insensitive" or "hormone-refractory" prostate cancer. While numerous therapies impact biochemical response in the setting of CRPC, there remains unmet medical need. New therapies that extend survival of patients beyond that provided by chemotherapy are needed.

The mechanisms of tumor progression to castration-resistance are unclear, but preclinical studies suggest that functional loss of the tumor suppressor gene PTEN and subsequent up-regulation of Akt, which is upstream of mTOR, may be involved in prostate cancer progression and metastasis. Based on these observations, it is hypothesized that mTOR inhibitor temsirolimus may prolong hormone sensitivity and delay disease progression in castration-resistant prostate cancer patients before antiandrogen withdrawal.

This study will assess efficacy on the basis of serum levels of PSA, an established surrogate endpoint for efficacy in prostate cancer.


Recruitment information / eligibility

Status Terminated
Enrollment 5
Est. completion date April 2012
Est. primary completion date April 2012
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility INCLUSION CRITERIA

- Histologically-confirmed adenocarcinoma of the prostate, characterized as symptomatic castration-resistant prostate cancer (CRPC)

- Serum PSA = 2 ng/mL

- Rising PSA on 3 consecutive occasions at least 1 week apart (not limited to the 30-day screening period)

- Failure of bilateral orchiectomy and/or therapy with an LHRH agonist and bicalutamide

- Castrate level of testosterone (< 50 ng/dL)

- Currently being treated with bicalutamide

- No prior antiandrogen therapy except bicalutamide

- Age = 18 years

- Life expectancy > 6 months

- Performance status

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- OR

- Karnofsky performance status = 80%

- Ability to understand and the willingness to sign a written informed consent

EXCLUSION CRITERIA

- Radiotherapy for prostate cancer within 28 days prior to Day 1, except single-fraction radiotherapy for pain control

- Prior treatment with mTOR inhibitors

- Prior treatment with chemotherapy for prostate cancer

- Symptomatic bone metastases (ie, asymptomatic bone metastases are eligible)

- Visceral metastases

- Absolute neutrophil count (ANC) < 1500/uL

- Platelet count = 100 x 10e9/L

- Total bilirubin = 1.5 x Upper Limit of Normal (ULN)

- Alkaline phosphatase > 2.5 x ULN

- AST > 2.5 x ULN

- ALT > 2. 5x ULN

- Serum creatinine > 2.0 mg/dL

- Hemoglobin < 9 g/dL

- Men with reproductive potential who do not agree to use an accepted and effective method of contraception during the study treatment period and for at least 3 months after completion of the study treatment

- History of other malignancies within 5 years except for tumors with a negligible risk for metastasis or death, such as adequately-controlled basal cell carcinoma, squamous-cell carcinoma of the skin, or early-stage bladder cancer

- Participation in another experimental drug study either planned or within 4 weeks of the first study treatment

- Persistent Grade = 1 AEs due to prior drug therapy, including investigational drugs, administered more than 14 days before study enrollment

- Previously treated or other known brain metastases

- Ongoing or active infection

- Symptomatic congestive heart failure, New York Heart Association Grade II or greater

- Unstable angina pectoris

- Cardiac arrhythmia

- Significant vascular disease (eg, aortic aneurysm, aortic dissection)

- Symptomatic peripheral vascular disease

- Psychiatric illness/social situations that would limit compliance with study requirements

- Other uncontrolled intercurrent illness

- Known to be positive for the human immunodeficiency virus (HIV) infection and receiving antiretroviral therapies (HIV positive not requiring antiretroviral therapy iseligible if all other entry criteria are meet)

- Inability to comply with study and/or follow-up procedures

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Temsirolimus
Temsirolimus is an inhibitor of the mammalian target of rapamycin (MTOR, aka HGNC:3942) IUPAC name: (1R,2R,4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontin-3-yl]propyl}-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate
Casodex (bicalutamide)
Casodex (bicalutamide) 50 mg/day PO

Locations

Country Name City State
United States Stanford University School of Medicine Stanford California

Sponsors (4)

Lead Sponsor Collaborator
Sandy Srinivas American Society of Clinical Oncology, National Comprehensive Cancer Network, Wyeth is now a wholly owned subsidiary of Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Reduction in Serum PSA Proportion of subjects with > 50% drop in serum PSA as compared to baseline, assessed at 16 weeks 12 weeks treatment, with primary outcome assessed at 16 weeks No
See also
  Status Clinical Trial Phase
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A